ALLMedicine™ Cutaneous Candidiasis Center

May 29th, 2021 - Congenital cutaneous candidiasis in one infant among a twin sibling pair.|2021|Akutsu A,Otsubo Y,Suzumura H,Yoshihara S,|

Feb 5th, 2021 - Congenital cutaneous candidiasis is an infrequent invasive fungal infection that usually appears in the first days of life. Extremely low birth weight infants are the most frequently affected. Classic presentation includes diffuse extensive erythe...

Mar 20th, 2020 - Auto-immune polyendocrinopathy syndrome type I is a rare genetic disease, usually revealed by chronic superficial candidiasis and autoimmune endocrine dysfunction in childhood. We report the cases of 2 children, a 4 years-11 months old boy and 13 ...

Feb 6th, 2020 - Jarisch-Herxheimer reaction (JHR) is an acute and self-limited condition, which commonly occurs after treatment for spirochetal infections. Probably, it corresponds to a transient immunological reaction to endotoxin-like products released from the...

Nov 21st, 2019 - Candida albicans is an opportunistic fungal pathogen of clinical importance and is the primary cause of fungal-associated wound infections, sepsis, or pneumonia in immunocompromised individuals. With the rise in antimicrobial resistance, it is bec...

May 31st, 2018 - The FP recognized that this was a case of allergic contact dermatitis (ACD), based on the clinical presentation. The distribution of the erythema, scale, and post-inflammatory hyperpigmentation was highly suggestive of an ACD to nickel.

Jan 18th, 2018 - Alternative regimens may be considered in patients who are intolerant to the treatment regimens or when the infection is refractory to the antifungal regimen. The combination of amphotericin B and flucytosine has been recommended in several specia...

Jun 6th, 2017 - The Diagnosis: Langerhans Cell Histiocytosis Langerhans cell histiocytosis (LCH) is a clonal proliferative disorder of Langerhans cells that can affect any organ, most commonly the skin and bones. It typically develops in children aged 1 to 3 year.

Sep 30th, 2015 - Action Points The interleukin (IL)-17A inhibitor secukinumab was significantly more effective than placebo in the treatment of psoriatic arthritis in a phase III study, a finding that supported IL-17A as a therapeutic target in this disorder. Note...